Integra LifeSciences (NASDAQ:IART) Shares Gap Down – What’s Next?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares gapped down before the market opened on Wednesday. The stock had previously closed at $13.33, but opened at $12.77. Integra LifeSciences shares last traded at $13.27, with a volume of 71,069 shares traded.

Key Headlines Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra exceeded third-quarter adjusted earnings expectations, reporting adjusted EPS of $0.59 versus the $0.56 consensus estimate. GAAP EPS recovered to $0.19 from a year-earlier loss of $0.07, while operating cash flow reached $96 million. Integra LifeSciences Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Specialty Surgery revenue grew 3.9% year over year, led by 6.5% organic growth in Neurosurgery. Integra also completed a $2.1 billion refinancing that extended maturities, reduced near-term refinancing risk and helped lower net debt to approximately $1.5 billion. Integra LifeSciences’ Refinancing
• Neutral Sentiment: Management reaffirmed its 2026 revenue guidance of $1.634 billion to $1.654 billion and adjusted EPS guidance of $2.30 to $2.40. However, the fourth-quarter revenue outlook implies a year-over-year decline of up to 5.2%, limiting the positive impact of the reaffirmation. Integra Fourth-Quarter Revenue Outlook
• Negative Sentiment: Quarterly revenue of $411.2 million fell short of the $413.2 million consensus estimate. Tissue Reconstruction revenue declined 2.2%, and flooding at the Cincinnati facility reduced revenue by approximately $7 million; management also cited a slower recovery timeline and softer business trends. Integra Revenue Miss and Flooding Impact
• Negative Sentiment: Analysts lowered their targets: Citigroup cut its target to $14 and maintained a neutral rating, JPMorgan reduced its target to $14 with an underweight rating, and Citizens JMP lowered its target to $22 while retaining market outperform. The cuts signal reduced confidence in near-term growth. Citizens JMP Integra Price Target
• Negative Sentiment: The refinancing improves liquidity but is expected to increase Integra’s effective interest rate by roughly 100 to 200 basis points, adding pressure to earnings and cash flow. Separately, law firms announced investigations into potential securities-law violations, creating an additional headline and litigation risk. Integra Securities Fraud Investigation

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Truist Financial cut their price objective on Integra LifeSciences from $19.00 to $15.00 and set a “hold” rating on the stock in a report on Wednesday, October 14th. BMO Capital Markets restated a “market perform” rating and issued a $14.00 price objective (down from $15.00) on shares of Integra LifeSciences in a research note on Thursday. Wells Fargo & Company set a $13.00 target price on Integra LifeSciences and gave the stock an “equal weight” rating in a report on Thursday. Citigroup reiterated an “outperform” rating on shares of Integra LifeSciences in a research report on Thursday. Finally, JPMorgan Chase & Co. dropped their target price on Integra LifeSciences from $17.00 to $14.00 and set an “underweight” rating on the stock in a research report on Thursday. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $17.00.

Integra LifeSciences Stock Performance

The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. The firm’s fifty day moving average price is $15.44 and its two-hundred day moving average price is $15.58. The stock has a market capitalization of $958.13 million, a PE ratio of -136.87, a price-to-earnings-growth ratio of 0.64 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.03. The firm had revenue of $411.18 million for the quarter, compared to the consensus estimate of $413.16 million. Integra LifeSciences had a net margin of 0.79% and a return on equity of 18.74%. During the same period in the prior year, the firm posted ($0.07) earnings per share. As a group, equities research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.35 EPS for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently modified their holdings of IART. Inspire Investing LLC increased its position in shares of Integra LifeSciences by 5.2% in the third quarter. Inspire Investing LLC now owns 39,168 shares of the life sciences company’s stock valued at $638,000 after buying an additional 1,929 shares in the last quarter. Sequoia Financial Advisors LLC raised its stake in shares of Integra LifeSciences by 221.7% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 45,785 shares of the life sciences company’s stock worth $822,000 after buying an additional 31,552 shares during the period. WINTON GROUP Ltd acquired a new position in shares of Integra LifeSciences during the 2nd quarter worth approximately $1,843,000. Integrated Wealth Concepts LLC acquired a new position in shares of Integra LifeSciences during the 2nd quarter worth approximately $84,000. Finally, Corient Private Wealth LP raised its stake in shares of Integra LifeSciences by 66.9% during the 2nd quarter. Corient Private Wealth LP now owns 22,749 shares of the life sciences company’s stock worth $409,000 after buying an additional 9,120 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.